Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Rossijskij Bioterapevticeskij Zurnal is Scopus-indexed (Q4, CiteScore 0.4). Published by ABV-press Publishing House.
Checked against the index lists dated .
ISSN 1726-9784Verify ISSN ↗1726-9792Verify ISSN ↗
Publisher: ABV-press Publishing House
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 391 / 428 | 8th | Q4 |
| Cancer Research | 222 / 233 | 4th | Q4 |
| Applied Microbiology and Biotechnology | 129 / 134 | 4th | Q4 |
| Immunology | 240 / 243 | 1st | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q4, CiteScore 0.4.
Rossijskij Bioterapevticeskij Zurnal is Q4 in Oncology (rank 391 of 428), Q4 in Cancer Research (rank 222 of 233) and Q4 in Applied Microbiology and Biotechnology (rank 129 of 134), by CiteScore 2025. It is ranked in 4 subject areas in all.
Rossijskij Bioterapevticeskij Zurnal is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.4, quartile Q4, 8th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.120, quartile Q4, with an H-index of 6.
Rossijskij Bioterapevticeskij Zurnal is published by ABV-press Publishing House. Its print ISSN is 1726-9784 and its online ISSN is 1726-9792.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Rossijskij Bioterapevticeskij Zurnal has an h-index of 10 and a 2-year mean of 0.23 citations per paper (OpenAlex). Its Scopus CiteScore is 0.4, quartile Q4. On 2-year citations it ranks #379 of 424 Scopus journals in Oncology.
Rossijskij Bioterapevticeskij Zurnal published 38 papers in 2025; its busiest recent year was 2017 with 55. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2023–2026), authors are most often from Russia (95.3%), United Kingdom (1.1%) and France (1.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.